Methods for identifying and using IKK inhibitors

Details Methods for identifying and using IKK inhibitors Methods for identifying and using IKK inhibitors

2006-05-30

2006-05-30

Weddington, Kevin E. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

Reexamination Certificate

active

07053119

ABSTRACT:
The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.

REFERENCES:
patent: 4559157 (1985-12-01), Smith
patent: 4608392 (1986-08-01), Jacquet
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch
patent: 4946778 (1990-08-01), Ladner
patent: 4965188 (1990-10-01), Mullis
patent: 4992478 (1991-02-01), Geria
patent: 6180681 (2001-01-01), Amici
patent: 6649654 (2003-11-01), Karin et al.
patent: 90/13678 (1990-11-01), None
Ausubel et al. (eds.), “Immunology,” inCurrent Protocols in Molecular Biology,New York: John Wiley & Sons, Chapter 11 (2000).
Baldwin, “The NF-kappa B and I-kappa B proteins: new discoveries and insights,”Annu Rev Immunol14:649-83 (1996).
Barnes and Karin, “Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases,”N Engl J Med336:1066-71 (1997).
Cole et al., “The EBV-hybridoma technique and its application to human lung cancer,” inMonoclonal Antibodies and Cancer Therapy,Reisfeld and Sell (eds.), New York: Alan R. Liss pp. 77-96 (1985).
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,”Proc Natl Acad Sci U S A80:2026-30 (1983).
Delhase et al., “Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation,”Science284:309-13 (1999).
DiDonato et al., “A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB,”Nature388:548-54 (1997).
Fukushima et al., “Prostaglandin J2—anti-tumour and anti-viral activities and the mechanisms involved,”Eicosanoids3:189-99 (1990).
Gilroy et al., “Inducible cyclooxygenase may have anti-inflammatory properties,”Nat Med5:698-701 (1999).
Gray et al., “Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors,”Science281:533-8 (1998).
Hirose et al., “Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis,”J Am Soc Nephrol9:408-16 (1998).
Huse et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda,”Science246:1275-81 (1989).
Jiang et al., “PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines,”Nature391:82-6 (1998).
Jones et al., “Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing,”Nat Med5:1418-23 (1999).
Karin and Delhase, “JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?,”Proc Natl Acad Sci U S A95:9067-9 (1998).
Kohler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature256:495-7 (1975).
Kozbor and Roder, “The production of monoclonal antibodies from human lymphocytes,”Immunology Today4:72-79 (1983).
Leung et al., “Increased in vitro bone resorption by monocytes in the hyper-immunoglobulin E syndrome,”J Immunol140:84-8 (1988).
Maniatis et al., “Regulation of inducible and tissue-specific gene expression,”Science236:1237-45 (1987).
Newton et al., “Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta,”Biochem Biophys Res Commun237:28-32 (1997).
Offenbacher et al., “The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss,”J Periodontal Res21:101-12 (1986).
Ricote et al., “The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,”Nature391:79-82 (1998).
Rossi et al., “2-Cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity,”J Biol Chem271:32192-6 (1996).
Rossi et al., “Inhibition of nuclear factor kappa B by prostaglandin A1: an effect associated with heat shock transcription factor activation,”Proc Natl Acad Sci U S A94:746-50 (1997).
Rothwarf et al., “IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex,”Nature395:297-300 (1998).
Sambrook et al.,Molecular Cloning A Laboratory Manual,New York: Cold Spring Harbor Laboratory Press pp. 7.39-7.52, 9.31-9.58, & 16.7-16.8,(1989).
Santoro et al., “Prostaglandin A compounds as antiviral agents,”Science209:1032-4 (1980).
Santoro et al., “Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells,”Proc Natl Acad Sci U S A86:8407-11 (1989).
Santoro et al., “Antiviral activity of cyclopentenone prostanoids,”Trends Microbiol5:276-81 (1997).
Serhan et al., “Lipid mediator networks in cell signaling: update and impact of cytokines,”FASEB J10:1147-58 (1996).
Staels et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators,”Nature393:790-3 (1998).
Tanaka et al., “Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice,”Immunity10:421-9 (1999).
Yamaoka et al., “Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation,”Cell93:1231-40 (1998).
Yin et al., “The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta,”Nature396:77-80 (1998).
Zandi et al., “Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate,”Science281:1360-3 (1998).
Rossi et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase,”Nature403:103-108 (2000).

Affiliated with

Also associated with

Rating

Methods for identifying and using IKK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for identifying and using IKK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying and using IKK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3587334